GLP-1 Medications Comparison Chart 2026: Complete Guide

Seven FDA-approved GLP-1 medications are now available for diabetes and weight management, and they differ in ways that matter: dosing frequency, weight loss results, cost, and side effect profiles. Our GLP-1 comparison chart below breaks down every major option so you can walk into your next appointment knowing exactly what to ask.

What Are GLP-1 Medications and How Do They Compare?

GLP-1 receptor agonists are a class of medications that mimic incretin hormones naturally produced in your intestines. These hormones regulate blood sugar by stimulating insulin release when glucose levels rise and slowing gastric emptying to help you feel full longer. This dual mechanism makes them effective for both diabetes management and weight loss.

Seven FDA-approved GLP-1 medications are currently available: semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), dulaglutide (Trulicity), exenatide (Byetta, Bydureon), liraglutide (Victoza, Saxenda), and lixisenatide (Adlyxin). Each offers different injection frequencies, with options ranging from daily to weekly dosing. Similar to how proper bydureon dosage requires careful titration, all GLP-1 medications need gradual dose increases.

The medications differ significantly in their mechanisms. While most target only GLP-1 receptors, tirzepatide uniquely activates both GLP-1 and GIP receptors, potentially explaining its superior effectiveness. Both branded and compounded versions exist, though only FDA-approved medications guarantee consistent potency and safety standards.

When to Consider Each GLP-1 Medication Option

The choice of GLP-1 medication depends on your primary treatment goals and individual circumstances. Ozempic and Rybelsus work best for patients focused primarily on diabetes management with moderate weight loss as a secondary benefit. These semaglutide-based options provide excellent blood sugar control with average weight loss of 12-15%.

Wegovy and Zepbound are specifically approved for obesity treatment and deliver more dramatic weight loss results. Zepbound (tirzepatide) leads the field with clinical trial participants losing 15-22% of body weight. Mounjaro offers similar dual-receptor benefits for diabetes patients who need maximum metabolic improvement.

Trulicity and Victoza suit patients preferring established safety profiles with longer market histories. These medications have extensive cardiovascular outcome data, making them ideal for patients with heart disease concerns. Just as patients might combine medications when learning about ozempic with other diabetes medications , your doctor can help determine if GLP-1 therapy fits your current treatment plan.

Daily injection options like liraglutide work well for patients who prefer more frequent dosing control, while weekly injections offer convenience for busy lifestyles.

How GLP-1 Medications Work and Dosing Schedules

GLP-1 medications follow different dosing patterns that affect both effectiveness and side effects. Weekly injections include semaglutide, tirzepatide, and dulaglutide, while daily options include liraglutide and oral semaglutide (Rybelsus). The injection frequency doesn't necessarily correlate with effectiveness, but it does impact lifestyle considerations.

Dose escalation protocols vary significantly between medications. Most start with low doses and increase gradually over 4-12 weeks to minimize gastrointestinal side effects. Semaglutide typically starts at 0.25mg weekly and increases to 1mg over 8 weeks, while tirzepatide begins at 2.5mg weekly and can reach 15mg over 12-16 weeks.

The dual-receptor mechanism of tirzepatide sets it apart from single-action GLP-1 medications. By targeting both GLP-1 and GIP pathways, it provides enhanced glucose control and appetite suppression. This explains why patients often see superior results compared to traditional GLP-1 medications.

Injection pen mechanisms also differ between manufacturers. Some use pre-filled pens while others require cartridge insertion. Needle sizes vary from 4mm to 8mm, affecting comfort levels for different patients. Understanding these practical differences helps ensure successful long-term treatment adherence.

Effectiveness and Weight Loss Results by GLP-1 Medication

Clinical trial data reveals significant differences in effectiveness between GLP-1 medications. Tirzepatide demonstrates the highest weight loss results, with participants losing 15-22% of body weight in major studies. Semaglutide-based medications typically produce 12-15% weight loss, while older options like liraglutide average 8-12%.

HbA1c reduction varies from 1.5-2.4% across different medications, with tirzepatide again showing superior glycemic control. Most patients reach maximum effectiveness between 12-20 weeks, depending on the medication and final dose achieved. The gradual titration process means patience is required to see full benefits.

Cardiovascular benefits have been established for semaglutide and dulaglutide through dedicated outcome trials. These medications reduce major adverse cardiac events by 13-26% in high-risk patients. Tirzepatide cardiovascular outcome studies are ongoing, with results expected in the near term.

Real-world effectiveness often mirrors clinical trial results, though individual responses vary considerably. Factors like adherence, diet, exercise, and baseline health status significantly influence outcomes. Some patients respond better to certain medications due to genetic or metabolic differences.

GLP-1 Medication Cost and Insurance Coverage Compared

Cost is one of the most practical factors in any GLP-1 comparison chart, and the differences between medications can be significant. List prices without insurance typically range from roughly $900 to $1,400 per month for branded injectable options like Ozempic, Wegovy, Mounjaro, and Zepbound. Older agents such as Trulicity and Victoza sit at the lower end of that range, while newer dual-receptor options tend to carry higher sticker prices.

Insurance coverage changes the picture considerably. Many commercial plans cover GLP-1 medications prescribed for type 2 diabetes, which means Ozempic and Mounjaro are more consistently covered than Wegovy and Zepbound, which carry obesity-specific indications. Patients with employer-sponsored insurance who are prescribed a GLP-1 for diabetes can often bring their monthly out-of-pocket cost down to $25 or less using manufacturer savings cards.

Coverage for Weight Loss vs. Diabetes

Medicare Part D currently does not cover GLP-1 medications prescribed solely for weight loss, though coverage for diabetes indications is available. Medicaid coverage varies by state. This distinction matters because the same active ingredient, semaglutide, is sold as Ozempic for diabetes and as Wegovy for obesity, and insurers treat them differently.

For patients without coverage, compounded semaglutide and tirzepatide became widely available during the FDA shortage period, at costs sometimes 60-80% lower than branded versions. However, the FDA has warned that compounded versions are not held to the same manufacturing standards as FDA-approved drugs, and shortages of branded agents have been largely resolved as of 2025.

How to Find Out What You Will Pay

The fastest way to get a real number is to run a prior authorization check with your insurer before your doctor writes the prescription. Most plans require documentation of a qualifying diagnosis, a BMI threshold, or evidence that lifestyle interventions have been tried. Our AI doctor can help you understand what documentation is typically required and what questions to bring to your prescriber, so you are prepared before the visit rather than surprised after.

The Bottom Line

GLP-1 medications offer proven benefits for both diabetes management and weight loss, with clear differences in effectiveness, dosing, and cost between options. Tirzepatide leads in weight loss results due to its dual-receptor mechanism, while semaglutide-based medications provide excellent outcomes with established cardiovascular benefits. Cost considerations significantly impact accessibility, with insurance coverage and manufacturer programs essential for affordability. The choice between medications should balance clinical effectiveness, side effect tolerance, dosing convenience, and financial factors. Success requires proper medical supervision, gradual dose titration, and realistic expectations about timeline and results. Doctronic's AI-powered platform can help you understand these options and discuss which GLP-1 medication aligns best with your health goals and circumstances. Ready to take control of your health? Get started with Doctronic today.